Market Place
Sourcing Support
Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
05 Nov 2024 //
BUSINESSWIRE
Arrowhead targets rare disease patients with awareness campaign
05 Nov 2024 //
FIERCE PHARMA
Arrowhead Pharma Reports Inducement Grants under NASDAQ LR 5635(c)(4)
14 Oct 2024 //
BUSINESSWIRE
Arrowhead Files For ARO-INHBE Phase 1/2a Obesity Study
23 Sep 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Gets FDA Breakthrough Designation
10 Sep 2024 //
BUSINESSWIRE
Arrowhead Presents Phase 3 Data On Plozasiran For Familial Chylomicronemia
03 Sep 2024 //
BUSINESSWIRE
Arrowhead To Present Plozasiran Phase 3 Data At ESC 2024
21 Aug 2024 //
BUSINESSWIRE
After clearing out heart drug, Arrowhead maps out obesity development plans
15 Aug 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Announces $500M Financing With Sixth Street
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
08 Aug 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants Under NASDAQ Rule 5635(c)(4)
29 Jul 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
24 Jul 2024 //
BUSINESSWIRE
Arrowhead Axes Heart Disease Drug, Focuses on Another
26 Jun 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Advances Plozasiran to Phase 3 CAPITAN Trial
25 Jun 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals presents new RNAi-based obesity program data.
24 Jun 2024 //
BUSINESSWIRE
Arrowhead`s Plozasiran Successful Topline Familial Chylomicronemia Data
03 Jun 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
31 May 2024 //
BUSINESSWIRE
Arrowhead Presents Zodasiran Phase 2 Data In Mixed Hyperlipidemia
29 May 2024 //
BUSINESSWIRE
Arrowhead plots next steps for RNAi therapies after mid-stage win
29 May 2024 //
ENDPTS
Arrowhead`s cholesterol drug hits the mark again in ph. 2 trial
28 May 2024 //
FIERCE BIOTECH
Arrowhead: New Phase 2 Plozasiran Data In Mixed Hyperlipidemia Patients
28 May 2024 //
BUSINESSWIRE
Arrowhead Presents ARO-RAGE High Gene Knockdown In Asthma
20 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
09 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
02 May 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
29 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
26 Apr 2024 //
BUSINESSWIRE
Arrowhead Initiates ARO-CFB Kidney Disease Study
24 Apr 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
24 Apr 2024 //
BUSINESSWIRE
Arrowhead`s plozasiran could reach $700M-plus in sales: report
16 Apr 2024 //
FIERCE PHARMA
Arrowhead reports full Phase 2b data for lipid drug, but Ionis is a step ahead
08 Apr 2024 //
PRESS RELEASE
Arrowhead Announces Ph 2 Data of Plozasiran Published in JAMA Cardiology
07 Apr 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
01 Apr 2024 //
BUSINESSWIRE
Arrowhead Initiates Program for Plozasiran and Announces Upcoming Presentation
25 Mar 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1
08 Mar 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
04 Mar 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals jumps amid takeover speculation
28 Feb 2024 //
SEEKING ALPHA
Arrowhead Pharmaceuticals expands board, adds new director from April
22 Feb 2024 //
PRESS RELEASE
Arrowhead axes assets, but spares staff, to save $100M a year
07 Feb 2024 //
FIERCE BIOTECH
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
06 Feb 2024 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
22 Jan 2024 //
BUSINESSWIRE
Arrowhead Closes Underwritten Offering with Gross Proceeds of $450.0M
05 Jan 2024 //
BUSINESSWIRE
Arrowhead Announces Pricing of $450.0M Underwritten Offering of Common Stock
03 Jan 2024 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
29 Dec 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB
21 Dec 2023 //
BUSINESSWIRE
Arrowhead to Present at the 42nd Annual J.P. Morgan Healthcare Conference
20 Dec 2023 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
29 Nov 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1
28 Nov 2023 //
BUSINESSWIRE
Arrowhead to Participate in Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
16 Nov 2023 //
BUSINESSWIRE
Arrowhead Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
13 Nov 2023 //
BUSINESSWIRE
Arrowhead Pharma to Participate in Jefferies London Healthcare Conference
06 Nov 2023 //
BUSINESSWIRE
Arrowhead to Present New Phase 2 Data on Cardiometabolic Pipeline at AHA 2023
02 Nov 2023 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming October 2023 Conferences
03 Oct 2023 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
27 Sep 2023 //
BUSINESSWIRE
Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023
11 Sep 2023 //
BUSINESSWIRE
Arrowhead Pharmaceuticals to Participate in Upcoming September 2023 Conferences
01 Sep 2023 //
BUSINESSWIRE
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results
07 Aug 2023 //
PRESS RELEASE
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Third Quarter Results
24 Jul 2023 //
BUSINESSWIRE
Arrowhead Files for Regulatory Clearance to Initiate a Ph 1/2 Study of ARO-DUX4
17 Jul 2023 //
BUSINESSWIRE
Arrowhead Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
06 Jul 2023 //
BUSINESSWIRE
